The role of inflammation, Iron, And nutritional status in cancer-related anemia: Results of a large, Prospective, Observational study

Haematologica

Volumn 100, Issue 1, 2015, Pages 124-132

  Macciò, Antonio ^a   Madeddu, Clelia ^b   Gramignano, Giulia ^c   Mulas, Carlo ^d   Tanca, Luciana ^a   Cherchi, Maria Cristina ^a   Floris, Carlo ^e   Omoto, Itaru ^f   Barracca, Antonio ^a   Ganz, Tomas ^g  

^a Ospedale Oncologico A Businco   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c NS Bonaria Hospital   (Italy)

^d Sirai Hospital   (Italy)

^e Nuova Casa di Cura   (Italy)

^f KAGOSHIMA UNIVERSITY   (Japan)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLESTEROL; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; LEPTIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; IRON;

ADULT; AGED; ANEMIA; ARTICLE; CANCER STAGING; CANCER THERAPY; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; INFLAMMATION; IRON METABOLISM; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PROSPECTIVE STUDY; QUANTITATIVE ASSAY; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; IMMUNOLOGY; ITALY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS;

ADULT; AGED; ANEMIA; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; INFLAMMATION; IRON; ITALY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; NUTRITIONAL STATUS; OXIDATIVE STRESS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84920195700     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.112813     Document Type: Article

References (54)

1. The Lancet Oncology. Keeping patients front and centre in the era of negative results. Lancet Oncol. 2013;14(10):909.
2. Spivak JL, Gascón P, Ludwig H. Anemia management in oncology and hematology. Oncologist. 2009;14(Suppl 1):43-56.
3. Steinmetz T, Totzke U, Schweigert M, Mittermüller J, Nawka S, Tesch H, et al. A prospective observational study of anaemia management in cancer patients-results from the German Cancer Anaemia Registry. Eur J Cancer Care. 2011;20(4):493-502.
4. Waters JS, O'Brien ME, Ashley S. Management of anemia in patients receiving chemotherapy. J Clin Oncol. 2002;20 (2):601-3.
5. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10): 1011-23.
6. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992;80(7):1639-47.
7. Streetz KL, Wüstefeld T, Klein C, Manns MP, Trautwein C. Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand). 2001;47(4):661-73.
8. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-6.
9. Bode JG, Albrecht U, Häussinger D, Heinrich PC, Schaper F. Hepatic acute phase proteins--regulation by IL-6-and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol. 2012;91(6-7):496-505.
10. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-54.
11. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62:347-60.
12. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood. 2005;106(6):2196-9.
13. Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Radic Biol Med. 2012;52(9):2013-37.
14. Neumcke I, Schneider B, Fandrey J, Pagel H. Effects of pro-and antioxidative compounds on renal production of erythropoietin. Endocrinology. 1999;140(2):641-5.
15. Takeda A, Toda T, Shinohara S, Mogi Y, Matsui N. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis. 2002;40(1):104-9.
16. Stenvinkel P, Heimbürger O, Lönnqvist F, Bárány P. Does the ob gene product leptin stimulate erythropoiesis in patients with chronic renal failure? Kidney Int. 1998;53(5):1430-1.
17. Barbot AC, Mussault P, Ingrand P, Tournai JM. Assessing 2-month clinical prognosis in hospidalized patients with advanced solid tumors. J Clin Oncol. 2008;26(15):2538-43.
18. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292-7.
19. Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickli H, et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int. 2004;66(3):1206-11.
20. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633-41.
21. Zipperer E1, Post JG, Herkert M, Kündgen A, Fox F, Haas R, et al. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome. Ann Hematol. 2013;92(12):1617-23.
22. Kroot JJ, van Herwaarden AE, Tjalsma H, Jansen RT, Hendriks JC, Swinkels DW. Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol. 2012;87(10):977-83.
23. Macciò A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 2005;106(1):362-7.
24. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998;18(8):555-9.
25. Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol. 1994;68(5):215-23.
26. Davis SL, Littlewood TJ. The investigation and treatment of secondary anaemia. Blood Rev. 2012;26(2):65-71.
27. Schrijvers D, De Samblanx H, Roila F; ESMO Guidelines Working Group: Erythropoiesisstimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol. 2010;21(Suppl 5):v244-7.
28. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-306.
29. Falkensammer CE, Thurnher M, Leonhartsberger N, Ramoner R. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int. 2011;107(12):1893-8.
30. Goodnough LT. Erythropoietin and ironrestricted erythropoiesis. Exp Hematol. 2007;35(4 Suppl 1):167-72.
31. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7): 2461-3.
32. Basseri RJ, Nemeth E, Vassilaki ME, Basseri B, Enayati P, Shaye O, et al. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. J Crohns Colitis. 2012;7 (8):e286-91.
33. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1051-6.
34. Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14(11):3262-7.
35. Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol. 2010;28(15):2538-43.
36. Shu T, Jing C, Lv Z, Xie Y, Xu J, Wu J. Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis. Eur J Haematol. 2014 Jun 21 (Epub ahead of print).
37. Durigova A, Lamy PJ, Thezenas S, Pouderoux S, Montels F, Romieu G, et al. Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification. Clin Chem Lab Med. 2013;51 (9):1833-41.
38. Ludwig H, Muldur E, Endler G, Hubl W. Prevealence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24(7):1886-92.
39. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y. Prevalence and management of cancer related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012;23(8):1954-62.
40. Beguin Y, Aapro M, Ludwig H, Mizzen L, Osterborg A. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis--a critical review. Crit Rev Oncol Hematol. 2014;89(1):1-15.
41. Spivak JL. Iron and the anemia of chronic disease: vindication for the non-essential role of iron supplementation. Oncology. 2011;25(5): 421-3.
42. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapyassociated anemia. J Clin Oncol. 2011;29 (1):97-105.
43. Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: openlabel, randomized controlled study. Oncologist. 2010;15(8):894-902.
44. Lee MJ, Fried SK. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab. 2009;296(6): E1230-8.
45. Macciò A, Madeddu C, Massa D Astara G, Farci D, Melis GB, et al. Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. J Cell Mol Med. 2009;13(9B):3951-9.
46. Hung SC, Tung TY, Yang CS, Tarng DC. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients. Am J Kidney Dis. 2005;45(6):1073-83.
47. Naviaux RK. Oxidative shielding or oxidative stress? J Pharmacol Exp Ther. 2012; 342(3):608-18.
48. Millonig G, Ganzleben I, Peccerella T, Casanovas G, Brodziak-Jarosz L, Breitkopf-Heinlein K, et al. Sustained submicromolar H2O2 levels induce hepcidin via signal transducer and activator of transcription 3 (STAT3). J Biol Chem. 2012;287(44):37472-82.
49. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2001;38(6):1251-63.
50. Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. 2013; 28(7):1936-45.
51. Steinmetz HT, Tsamaloukas A, Schmitz S, Wiegand J, Rohrberg R, Eggert J, et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer. 2010;19(2):261-9.
52. Hsu SP, Chiang CK, Yang SY, Chien CT. Nacetylcysteine for the management of anemia and oxidative stress in hemodialysis patients. Nephron Clin Pract. 2010;116(3): c207-16.
53. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610-8.
54. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011;11(12):1663-8.